Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA-GPRC5D CAR-T in Relapsed/Refractory Multiple Myeloma
NCT07376720Not yet recruiting
- Start
- Feb 2026
- Primary completion
- Oct 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of Ori-CAR-002 in multiple myeloma (MM). Primary endpoint: Overall Survival at 24 months. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
Ori-CAR-002
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07376720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07376720.